The Insiders Fund, LP on GE HealthCare Technologies Inc.
Thesis
The Insiders Fund expects GE HealthCare to benefit if investor interest broadens from AI infrastructure companies toward healthcare. Its established positions in imaging and ultrasound and growth in nuclear medicine support the case. The proposed SOFIE Biosciences acquisition would expand its radiopharmaceutical operations, while a substantial equipment backlog and AI-enabled innovation add to operational momentum. The manager believes the stock’s prior underperformance leaves room for a positive re-rating, although the letter’s claim about significant insider buying conflicts with its own report of no insider trades during the quarter.
“Strong position in imaging and ultrasound markets combined with the belief the market will rotate into a broader sector other than AI infrastructure names.”
Key risks
- Supply-chain inflation
- Volatile demand in China
- The stock has lagged despite favorable operating developments
- The claimed insider-buying catalyst is not reflected in the quarter’s disclosed insider transactions